Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Knight, MD
Celgene
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Palo Verde Hematology Oncology
Glendale, Arizona, United States
- Mayo Clinic
Scottsdale, Arizona, United States
- Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
- Providence St. Joseph Medical Center/cancer Center
Burbank, California, United States
- Wilshire Oncology Medical Group, Inc.
La Verne, California, United States
- Institute for Myeloma and Bone
Los Angeles, California, United States
- Cancer Care Associates
Redondo Beach, California, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Northwest Georgia Oncology Centers
Marietta, Georgia, United States
- Atlanta Cancer Care-Roswell
Roswell, Georgia, United States
- Northwestern University Med Ctr
Chicago, Illinois, United States
- Midwest Cancer Research Group
Skokie, Illinois, United States
- University of Maryland Medical Center
Baltimore, Maryland, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- University of Massachusetts
Worcester, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Nevada Cancer Center
Las Vegas, Nevada, United States
- Suny Health Science Center at Brooklyn
Brooklyn, New York, United States
- St. Vincent'S Comprehensive Cancer Center
New York, New York, United States
- Carolina Hematology-Oncology Associates
Charlotte, North Carolina, United States
- Cleveland Clinic Myeloma Program Hematology & Medical Oncology /r35
Cleveland, Ohio, United States
- Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jul 2003
- Primary completion
- 1 Oct 2006
- Completion
- 1 Mar 2007
- Last update posted
- 12 Nov 2019
- Registered enrollment
- 222
- Registry id
- NCT00065351
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.